Lotilaner in the form of an eye solution (0.25%) is the first drug approved by the US FDA for the treatment of Demodex blepharitis, which works as an antiparasitic to paralyze the mites.[1] A study examined the effectiveness of this solution compared to a vehicle control in patients who had both Demodex blepharitis and Meibomian gland disease. After 43 days of treatment, 47% of lotilaner-treated patients achieved moderate or better meibomian gland disease status, which was significantly higher than 21% in the control group.[1] At day 85, the difference widened even more, with 63% of lotilaner patients achieving improvement compared to 24% in the control group. An improvement of at least one grade of severity was experienced by 63% of patients with lotilaner versus 38% with vehicle at 43 days and 74% versus 39% at 85 days. The study did not report any serious treatment-related adverse events. The results confirm that six weeks of treatment with lotilaner significantly improved the status of Meibomian gland disease in patients with Demodex blepharitis.